- Design
- Systematic review and random-effects meta-analysis
- Population
- 9 studies, 795 adults with MASLD or MASH
- Primary outcome
- Liver fat, enzymes, weight and HbA1c
- Effect
- Liver fat MD −3.17 (−4.06 to −2.29); ALT −15.2 U/L
A systematic review and meta-analysis pooled nine studies of 795 adults with MASLD or MASH treated with GLP-1 receptor agonists between 2019 and 2025.
Treatment was associated with lower liver fat content (mean difference −3.17, 95% CI −4.06 to −2.29), body weight (−4.68), ALT (−15.2 U/L), AST (−9.9 U/L) and HbA1c (−0.78%). Nausea and vomiting were more common, but serious adverse events did not differ.
The evidence is a mix of small studies over short periods, and none established effects on fibrosis, histology or liver outcomes. Even so, many patients with MASLD also have obesity or type 2 diabetes, where these drugs are already indicated. For them, the liver is an additional reason to choose a GLP-1 agent.
- Consider a GLP-1 receptor agonist for patients with MASLD who also have obesity or type 2 diabetes.
- Assess fibrosis risk with FIB-4 or elastography before and during treatment.
- Warn patients about nausea and vomiting, and titrate slowly.
- Continue weight loss, alcohol reduction and cardiovascular risk management as the foundation.
Why it matters
Most patients with MASLD already qualify for a GLP-1 agent on other grounds, so the liver benefit can be added without a new indication.
Don't overread it
Nine small studies of surrogate outcomes; effects on fibrosis and liver-related events were not established.
The statistics, in plain English
The reductions in liver fat and enzymes are consistent and their intervals exclude no effect. They are surrogate measures; whether they translate into less fibrosis or fewer liver events is not shown here.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for gastroenterology & hepatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free